NURS 6521 Week 8 Hormonal Agent Risk Post Example

Week 8 Discussion: Initial Post

A Request for the Combined Pill After an Unprovoked Blood Clot: Why Estrogen Is Off the Table and What Is Not

My patient is fictional. L.B. is a 31-year-old graphic designer who asks to restart the combined estrogen-progestin pill she took in her twenties, because it kept her periods light and regular and helped her acne. Two years ago she had an unprovoked deep vein thrombosis in her left leg, treated with six months of apixaban, which she has now stopped. She does not smoke, her blood pressure is normal, and she wants reliable contraception for at least three years. Her request is reasonable on its face, and her reasons for wanting the pill are worth keeping in view.

The concern is mechanism. Oral estrogen passes through the liver first, where it increases hepatic synthesis of several clotting factors, including fibrinogen, prothrombin, and factors VII, VIII, and X, while lowering the natural anticoagulants antithrombin and protein S and producing an acquired resistance to activated protein C (Rosenthal & Burchum, 2021). The net effect is a shift toward coagulation. In most women the absolute risk stays small, but L.B. has already shown that her clotting system can tip over without a provoking cause. Adding an agent that pushes the same system in the same direction is the reason the answer is no, not the category number itself.

The CDC's contraceptive eligibility guidance, the US MEC, rates each method by condition. For a woman with a history of deep vein thrombosis who is not on anticoagulation and is at higher risk of recurrence, which an unprovoked clot places her in, combined hormonal methods are category 4, an unacceptable health risk (Nguyen et al., 2024). That applies equally to the patch and the ring, which deliver estrogen through a different route but still raise clotting factors.

What remains is broad, and it deserves the most attention. The levonorgestrel intrauterine device, the etonogestrel implant, the progestin-only pill, and depot medroxyprogesterone are category 2 for her history, meaning the benefits generally outweigh the risks, and the copper intrauterine device is category 1 (Nguyen et al., 2024). Progestins do not raise hepatic clotting factors the way estrogen does. Matching what she valued in the pill, the levonorgestrel device reduces menstrual bleeding substantially, often to very light periods, and lasts up to eight years; I would offer it first. The implant is equally effective but causes unpredictable bleeding, which she may find worse than her current periods. The progestin-only pill requires strict daily timing. I would avoid depot medroxyprogesterone as a first choice because some observational data link it to higher venous thrombosis risk than other progestin methods, and it reduces bone density with long use. The copper device avoids hormones entirely but tends to make periods heavier. Her acne can be treated separately.

Reply to Christopher

Christopher, your 64-year-old patient with stable angina who uses isosorbide mononitrate and asks about sildenafil raises the one absolute contraindication in this class. Nitrates release nitric oxide, which activates guanylate cyclase in vascular smooth muscle and raises cyclic GMP. Sildenafil blocks phosphodiesterase type 5, the enzyme that breaks cyclic GMP down. Together they drive cyclic GMP much higher than either alone, and the combined vasodilation can cause severe, prolonged hypotension, dangerous in a man whose coronary perfusion already depends on pressure (Rosenthal & Burchum, 2021). I would add that the risk runs both ways: if he took sildenafil and then developed chest pain, emergency staff need to know before giving nitroglycerin, so that information belongs in his wallet as well as his chart.

Reply to Megan

Megan, you chose finasteride for your 68-year-old with bothersome urinary frequency and a weak stream, and I wonder whether that fits his main goal, which was relief before a long road trip next month. The two classes work on different components of the obstruction. Alpha-1 blockers such as tamsulosin relax smooth muscle in the prostate and bladder neck and improve symptoms within days. Five-alpha reductase inhibitors block conversion of testosterone to dihydrotestosterone, shrinking the gland over three to six months, and they help most when the prostate is clearly enlarged (Lerner et al., 2021). Do you know his prostate size? If it is modest, an alpha blocker alone may serve him better, with the reductase inhibitor added later if the gland is large.

References

Lerner, L. B., McVary, K. T., Barry, M. J., Bixler, B. R., Dahm, P., Das, A. K., Gandhi, M. C., Kaplan, S. A., Kohler, T. S., Martin, L., Parsons, J. K., Roehrborn, C. G., Stoffel, J. T., Welliver, C., & Wilt, T. J. (2021). Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I, initial work-up and medical management. Journal of Urology, 206(4), 806-817. https://doi.org/10.1097/JU.0000000000002183

Nguyen, A. T., Curtis, K. M., Tepper, N. K., Kortsmit, K., Brittain, A. W., Snyder, E. M., Cohen, M. A., Zapata, L. B., & Whiteman, M. K. (2024). U.S. medical eligibility criteria for contraceptive use, 2024. MMWR Recommendations and Reports, 73(4), 1-126. https://doi.org/10.15585/mmwr.rr7304a1

Rosenthal, L. D., & Burchum, J. R. (2021). Lehne's pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.). Elsevier.